KPA to demand compensation of Zyprexa tablet

Following the price cut of Lilly Korea's Zyprexa (olanzapine) tablet by 14 to 39.9 percent from December 1st in line with its re-designation as the first-line drug in treatment of psychosis, the Korea Pharmaceutical Association delivered its inquiry letter to the president of Lilly Korea, urging the company to compensate the differential prices including acceptance of returned goods, in a bid t...